Professor Jerald Radich

Jerald P. Radich, is Professor of Medicine at the University of Washington School of Medicine. He serves as Director of the Molecular Oncology Lab and holds the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center. He is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group.

He was the inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, and a past member of the Board of Scientific Counselors of the National Institute of Health Genome Research Institute.  He is the past-chair of the CML Committee of the National Comprehensive Cancer Network, the inaugural chair of the H. Jean Khoury Cure CML Consortium, a member of the European Leukemia Network CML committees, and is on the Scientific Board of the International CML Foundation and the Max Foundation. He currently leads the Laboratory Committee of the NCI AML Precision Medicine Initiative (“myeloMATCH”) and leads the Foundation of the NIH’s program in measurable residual disease in AML.

He earned his medical degree from the University of California, San Francisco (UCSF), followed by a residency at Brigham and Women’s Hospital and fellowship in hematology/oncology at Dana-Farber Cancer Institute.

Dr. Radich’s laboratory research centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia. In addition, the CLIA Molecular Oncology Lab provides the molecular diagnostic support for many institutional, U.S. Intergroup, international, and pharmaceutical trials, including the NCI Precision Medicine Initiative in AML (myeloMATCH).

Dr Radich was awarded the iCMLf Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring CML in the developing world, as well as the iCMLf's Rowley Prize in 2023 for his work on the biology of CML.